The role of botulinum toxin a in the management of lower urinary tract symptoms

Kirby RS: The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 2000, 56:3–6. Platz EA, Smit E, Curhan GC, et al.: Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in US men. Urology 2002, 59:877–883. Hald T: Urodynamics in benign prostatic hyperplasia: a survey. Prostate Suppl 1989, 2:69–77. Barry MJ, Fowler FJ Jr, Bin L, Oesterling JE: A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. J Urol 1997, 158:488–491, discussion 492. Kortt MA, Bootman JL: The economics of benign prostatic hyperplasia treatment: a literature review. Clin Ther 1996, 18:1227–1241. Verhamme KM, Dieleman JP, Bleumink GS, et al.: Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 2003, 44:539–545. Ball AJ, Feneley RC, Abrams PH: The natural history of untreated “prostatism.” Br J Urol 1981, 53:613–616. Nickel JC: Benign prostatic hyperplasia: does prostate size matter? Rev Urol 2003, 5:S12–S17. Lin VK, Wang D, Lee IL, et al.: Myosin heavy chain gene expression in normal and hyperplastic human prostate tissue. Prostate 2000, 44:193–203. Riehmann M, Bruskewitz R: Transurethral incision of the prostate and bladder neck. J Androl 1991, 12:415–422. Shapiro E, Tsitlik JE, Lepor H: Alpha 2 adrenergic receptors in canine prostate: biochemical and functional correlations. J Urol 1987, 137:565–570. Kaplan SA, Goluboff ET, Olsson CA, et al.: Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology 1995, 45:398–405. Savoca G, De Stefani S, Gattuccio I, et al.: Percutaneous ethanol injection of the prostate as minimally invasive treatment for benign prostatic hyperplasia: preliminary report. Eur Urol 2001, 40:504–508. Plante MK, Gross AL, Kliment J, et al.: Intraprostatic ethanol chemoablation via transurethral and transperineal injection. BJU Int 2003, 91:94–98. Plante MK, Bunnell ML, Trotter SJ, et al.: Transurethral prostatic tissue ablation via a single needle delivery system: initial experience with radio-frequency energy and ethanol. Prostate Cancer Prostatic Dis 2002, 5:183–188. Duchen LW: Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles. J Neurol Neurosurg Psychiatry 1970, 33:40–54. Chuang YC, Chancellor MB: The application of botulinum toxin in the prostate. J Urol 2006, 176:2375–2382. Kanagawa K, Sugimura K, Kuratsukuri K, et al.: Norepinephrine activates P44 and P42 MAPK in human prostate stromal and smooth muscle cells but not in epithelial cells. Prostate 2003, 56:313–318. Hedlund H, Andersson KE: Comparison of the responses to drugs acting on adrenoreceptors and muscarinic receptors in human isolated corpus cavernosum and cavernous artery. J Auton Pharmacol 1985, 5:81–88. Thiyagarajan M, Kaul CL, Ramarao P: Enhancement of alpha-adrenoceptor-mediated responses in prostate of testosterone-treated rat. Eur J Pharmacol 2002, 453:335–344. Roehrborn CG: Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. Rev Urol 2004, 6:121–127. Hansson J, Bjartell A, Gadaleanu V, et al.: Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate 2002, 53:50–59. Lin AT, Yang AH, Chen KK: Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol 2007, 52:582–589. Morris JL, Jobling P, Gibbins IL: Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons. Am J Physiol Heart Circ Physiol 2002, 283:H2627–H2635. Jung HH, Lauterburg T, Burgunder JM: Expression of neurotransmitter genes in rat spinal motoneurons after chemodenervation with botulinum toxin. Neuroscience 1997, 78:469–479. Scott AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980, 17:21–25. Dykstra DD, Sidi AA, Scott AB, et al.: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988, 139:919–922. Maria G, Brisinda G, Civello IM, et al.: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003, 62:259–264, discussion 264–265. Kuo HC: Prostate botulinum A toxin injection—an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005, 65:670–674. Larson TR, Huidobro C, Acevedo C, et al.: Intraprostatic injection of botulinum toxin in the treatment of symptomatic LUTS, including sequential MRIS for accurate changes in size of the prostate [abstract 1386]. Presented at the American Urological Association Annual Meeting. San Antonio, TX; May 21–26, 2005. Silva J, Silva C, Saraiva L, et al.: Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 2008, 53:153–159. Park DS, Cho TW, Lee YK, et al.: Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J 2006, 47:706–714. Chuang YC, Chiang PH, Yoshimura N, et al.: Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 2006, 98:1033–1037, discussion 1337.